Among @ eligible treated patients , median PFS was @ months for bevacizumab alone ( @ % CI , @ to @ months ) , @ months for bevacizumab plus temsirolimus ( @ % CI , @ to @ months ) , @ months for bevacizumab plus sorafenib ( @ % CI , @ to @ months ) , and @ months for sorafenib plus temsirolimus ( @ % CI , @ to @ months ) .